SMTL ID : 8bpv.1

Crystal structure of JAK2 JH1 in complex with pacritinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.70 Å

Oligo State

monomer

Ligands

1 x 6T3: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene(Non-covalent)

6T3.1: 22 residues within 4Å: Chain A: Q.39, L.40, G.41, F.45, V.48, A.65, K.67, V.96, M.114, E.115, Y.116, L.117, P.118, G.120, S.121, R.123, D.124, R.165, N.166, L.168, G.178, D.179 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:L.40, A:L.40, A:L.40, A:V.48, A:A.65, A:Y.116 Hydrogen bonds: A:L.117, A:L.117 Water bridges: A:D.124

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Miao, Y. et al., Structural basis for JAK2 inhibition by clinical stage inhibitors. To Be Published

Release Date

2023-11-29

Peptides

Tyrosine-protein kinase JAK2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase JAK2

Related Entries With Identical Sequence